The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
By using QDs, only the necessary colors for ideal images are contained in the screen. The first commercial application of quantum dots was the Sony XBR X900A series of flat panel televisions released in 2013. In June 2006, QD Vision announced technical success in making a proof-of-concept quantum dot display and show a bright emission in the visible and near infrared region of the spectrum. A QD-LED integrated at a scanning microscopy tip was used to demonstrate fluorescence near-field scanning optical microscopy (NSOM) imaging.
=== Disappearance === On 4 March 1998, at around 2:00 PM, Mendonça took his bicycle and cycled to his mother's workplace, located near the family home. He had asked his mother for permission to spend the afternoon riding in a car "with his friend Afonso" (Afonso Dias), a 22-year-old lorry driver. Mendonça's mother denied the request, and told him to go play in an abandoned lot outside her office.
Media related to Bananas and plantains as food at Wikimedia Commons Musapedia: "The banana knowledge compendium", maintained by ProMusa CGIAR's RTB Research Program Banana Page Banana and Plantain at the International Institute of Tropical Agriculture (IITA)
Sources: en.wikipedia.org
Einsteinium at The Periodic Table of Videos (University of Nottingham) Age-related factors in radionuclide metabolism and dosimetry: Proceedings – contains several health related studies of einsteinium
=== Other inventions === During the Upper Paleolithic, further inventions were made, such as the net (c. 22,000 or c. 29,000 BP) bolas, the spear thrower (c. 30,000 BP), the bow and arrow (c. 25,000 or c. 30,000 BP) and the oldest example of ceramic art, the Venus of Dolní Věstonice (c. 29,000 – c. 25,000 BP). Kilu Cave at Buku island, Solomon Islands, demonstrates navigation of some 60 km of open ocean at 30,000 BCcal. Early dogs were domesticated sometime between 30,000 and 14,000 BP, presumably to aid in hunting. However, the earliest instances of successful domestication of dogs may be much more ancient than this. Evidence from canine DNA collected by Robert K. Wayne suggests that dogs may have been first domesticated in the late Middle Paleolithic around 100,000 BP or perhaps even earlier. Archaeological evidence from the Dordogne region of France demonstrates that members of the European early Upper Paleolithic culture known as the Aurignacian used calendars (c. 30,000 BP). This was a lunar calendar that was used to document the phases of the moon. Genuine solar calendars did not appear until the Neolithic. Upper Paleolithic cultures were probably able to time the migration of game animals such as wild horses and deer. This ability allowed humans to become efficient hunters and to exploit a wide variety of game animals. Recent research indicates that the Neanderthals timed their hunts and the migrations of game animals long before the beginning of the Upper Paleolithic.
Social constructivists argue that technologies follow no natural progression, and they are shaped by cultural values, laws, politics, and economic incentives. Modern scholarship has shifted towards an analysis of sociotechnical systems, "assemblages of things, people, practices, and meanings", looking at the value judgments that shape technology. Cultural critic Neil Postman distinguished tool-using societies from technological societies and from what he called "technopolies", societies that are dominated by an ideology of technological and scientific progress to the detriment of other cultural practices, values, and world views. Herbert Marcuse and John Zerzan suggest that technological society will inevitably deprive humanity of its freedom and psychological health.
Sources: en.wikipedia.org
1985 Goldenes Ehrenzeichen, Republic of Austria 1994 Austrian Decoration for Science and Art, Republic of Austria 1997 Honorary Member, Slovak Chemical Society 2003 Cross of Merits, State of Tyrol 2004 Cross of Merits, Austria 2007 Cross of Honours in Science and Arts first class, Republic of Austria 2008 Jan-Weber-Medal of the Slovak Pharmaceutical Society 2010 Sitara-e-Qaid-i-Azam (Civil decoration of Pakistan) 2011 Knight Grand Cross (First Class of The Most Exalted Order of the White Elephant with Slash) According to the Theoretical Chemistry Genealogy Project, Bernd Michael Rode is the most successful doctoral thesis supervisor of German-speaking countries in the field of Theoretical Chemistry. Between 1976 and 2011 Prof. Rode has led not less than 70 students to their Ph.D. degree. Due to his close contacts to South-East-Asia many of them come from Asian countries.
== Pathophysiology == When phenylalanine cannot be metabolized by the body, a typical diet that would be healthy for people without PKU causes abnormally high levels of phenylalanine to accumulate in the blood, which is toxic to the brain. If left untreated (and often even in treatment), complications of PKU include severe intellectual disability, brain function abnormalities, microcephaly, mood disorders, irregular motor functioning, and behavioral problems such as attention deficit hyperactivity disorder, as well as physical symptoms such as a "musty" odor, eczema, and unusually light skin and hair coloration.
==== Vertebrates ==== In the early development of vertebrate embryos, growth and formation of muscle happens in successive waves or phases of myogenesis. The myosin heavy chain isotype is a major determinant of the specific fiber type. In zebrafish embryos, the first muscle fibers to form are the slow twitch fibers. These cells will undergo migration from their original location to form a monolayer of slow twitch muscle fibers. These muscle fibers undergo further differentiation as the embryo matures.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.